Skip to main content

Table 2 Treatment characteristics in ICU patients

From: Broncho-alveolar inflammation in COVID-19 patients: a correlation with clinical outcome

Treatment Survivors
(N = 16)
Non-survivors
(N = 12)
P value
Tocilizumab N(%) 4 (25) 4 (25) 0.6908
Remdesivir N(%) 3 (18.8) 4 (5) 0.6618
Hydroxychloroquine N(%) 12 (75) 12 (100) 0.1131
Ritonavir/Lopinavir N(%)a 7 (50) 9 (75) 0.1358
Corticosteroids N(%)b
 - Dexamethasone 0.4 mg·Kg− 1 4 (25) 5(42) 0.4319
 - Methylprednisolone 0.3 mg·Kg−1 0 (0) 1(8.3) 0.4286
 - Hydrocortisone 150 mg·die−1 1 (6.25) 1(8.3) > 0.999
Mechanical ventilationc
 - Vt/IBW -ml Kg−1d 7.85(7.6–8.85) 6.4 (6.1–8) 0.4275
 - PEEP -cmH20 11(8–13.25) 12 (8–12) 0.9073
  1. aData regarding the administration of Ritonavir/Lopinavir are missing for two patients who died and two who survived (14.8%)
  2. bData regarding the administration of steroids is missing for one dead patient (3.70%)
  3. cData regarding ventilation parameters are missing of two dead patients (7.41%)
  4. dVt/IBW Tidal volume/ideal body weight calculated using the gender-specific Acute Respiratory Distress Syndrome Network (ARDSnet) formulas [8]